Thymosin β4 and cardiac protection: Implication in inflammation and fibrosis

Annals of the New York Academy of Sciences

Volumn 1269, Issue 1, 2012, Pages 84-91

  Gupta, Sudhiranjan ^a   Kumar, Sandeep ^b   Sopko, Nikolai ^c   Qin, Yilu ^d   Wei, Chuanyu ^a   Kim, Il Kwon ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Antioxidative genes; Cardiac fibrosis; NF B; Thymosin 4

Indexed keywords

CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTEGRIN LINK KINASE; PHOSPHOTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; THYMOSIN BETA4; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; COLLAGEN SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; GENE SILENCING; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION;

EID: 84867380703     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06752.x     Document Type: Article

References (67)

1. Bubb, M.R. 2003. Thymosin beta 4 interactions. VitamHorm 66: 297-316.
2. Malinda, K.M., A.L. Goldstein and H.K. Kleinman 1997. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. Faseb J. 11: 474-481.
3. Goldstein, A.L., E. Hannappel & H.K. Kleinman 2005. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol. Med. 11: 421-429.
4. Hinkel, R. et al 2010. Thymosin beta4: a key factor for protective effects of eEPCs in acute and chronic ischemia. Ann. N. Y. Acad. Sci. 1194: 105-111.
5. Philp, D. et al 2003. The actin binding site on thymosin beta4 promotes angiogenesis. Faseb. J. 17: 2103-2105.
6. Low, T.L., S.K. Hu & A.L. Goldstein 1981. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyltransferase activity in thymocyte populations. Proc. Natl. Acad. Sci. U. S. A. 78: 1162-1166.
7. Dedova, I.V. et al 2006. Thymosin beta4 induces a conformational change in actin monomers. Biophys. J. 90: 985-992.
8. Au, J.K., E.M. De La Cruz & D. Safer 2007. Contributions from all over: widely distributed residues in thymosin beta-4 affect the kinetics and stability of actin binding. Ann. N. Y. Acad. Sci. 1112: 38-44.
9. Goldstein, A.L. et al 2012. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin. Biol. Ther. 12: 37-51.
10. Ehrlich, H.P. & S.W. Hazard, 3rd. 2010. Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts. Ann. N. Y. Acad. Sci. 1194: 118-124.
11. Sosne, G. et al 2006. Thymosin [beta]4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitro. Exp. Eye Res. 83: 502-507.
12. Sosne, G. et al 2010. Thymosin beta4 and corneal wound healing: visions of the future. Ann. N. Y. Acad. Sci. 1194: 190-198.
13. Sosne, G., P. Qiu & M. Kurpakus-Wheater 2007. Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent. Clin. Ophthalmol. 1: 201-207.
14. Bock-Marquette, I. et al 2004. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432: 466-472.
15. Smart, N. et al 2007. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445: 177-182.
16. Smart, N. et al 2010. Thymosin beta4 facilitates epicardial neovascularization of the injured adult heart. Ann. N. Y. Acad. Sci. 1194: 97-104.
17. Dube, K.N. et al 2012. Thymosin beta4 protein therapy for cardiac repair. Curr. Pharm. Des. 18: 799-806.
18. Kupatt, C., I. Bock-Marquette & P. Boekstegers 2008. Embryonic endothelial progenitor cell-mediated cardioprotection requires Thymosin beta4. Trends Cardiovasc. Med. 18: 205-210.
19. Qiu, F.Y. et al 2009. Thymosin beta4 induces endothelial progenitor cell migration via PI3K/Akt/eNOS signal transduction pathway. J. Cardiovasc. Pharmacol. 53: 209-214.
20. Bock-Marquette, I. et al 2009. Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. J. Mol. Cell Cardiol. 46: 728-738.
21. Swynghedauw, B. 1999. Molecular mechanisms of myocardial remodeling. Physiol. Rev. 79: 215-262.
22. Gonzalez, A. et al 2011. New targets to treat the structural remodeling of the myocardium. J. Am. Coll. Cardiol. 58: 1833-1843.
23. Srivastava, D. et al 2007. Thymosin beta4 is cardioprotective after myocardial infarction. Ann. N. Y. Acad. Sci. 1112: 161-170.
24. Shrivastava, S. et al 2010. Thymosin beta4 and cardiac repair. Ann. N. Y. Acad. Sci. 1194: 87-96.
25. Crockford, D. 2007. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Ann. N. Y. Acad. Sci. 1112: 385-395.
26. Yesilay, A.B. et al 2011. Thymosin beta4 levels after successful primary percutaneous coronary intervention for acute myocardial infarction. Turk KardiyolojiDernegiarsivi: Turk KardiyolojiDernegininyayinorganidir. 39: 654-660.
27. Lu, H. et al 2006. Integrin-linked kinase expression is elevated in human cardiac hypertrophy and induces hypertrophy in transgenic mice. Circulation 114: 2271-2279.
28. White, D.E. et al 2006. Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev. 20: 2355-2360.
29. Hannigan, G.E., J.G. Coles & S. Dedhar 2007. Integrin-linked kinase at the heart of cardiac contractility, repair, and disease. Circ. Res. 100: 1408-1414.
30. Knoll, R. et al 2007. Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation 116: 515-525.
31. Ding, L. et al 2009. Increased expression of integrin-linked kinase attenuates left ventricular remodeling and improves cardiac function after myocardial infarction. Circulation 120: 764-773.
32. Gu, R. et al 2012. Increased expression of integrin-linked kinase improves cardiac function and decreases mortality in dilated cardiomyopathy model of rats. PLoS One 7: e31279.
33. Legate, K.R., S.A. Wickstrom & R. Fassler 2009. Genetic and cell biological analysis of integrin outside-in signaling. Genes. Dev. 23: 397-418.
34. Fukuda, T. et al 2003. PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. J. Biol. Chem. 278: 51324-51333.
35. Fukuda, T. et al 2003. CH-ILKBP regulates cell survival by facilitating the membrane translocation of protein kinase B/Akt. J. Cell Biol. 160: 1001-1008.
36. Sopko, N. et al 2011. Significance of thymosin beta4 and implication of PINCH-1-ILK-alpha-Parvin (PIP) complex in human dilated cardiomyopathy. PLoS One 6: e20184.
37. Hinkel, R. et al 2008. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation 117: 2232-2240.
38. Zhou, B. et al 2012. Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. J. Mol. Cell Cardiol. 52: 43-47.
39. Martinon, F., A. Mayor & J. Tschopp 2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27: 229-265.
40. Banerjee, I. et al 2012. Thymosin beta 4 is dispensable for murine cardiac development and function. Circ. Res. 110: 456-464.
41. Yellon, D.M. & D.J. Hausenloy 2007. Myocardial reperfusion injury. N. Engl. J. Med. 357: 1121-1135.
42. Wrigley, B.J., G.Y. Lip & E. Shantsila 2011. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur. J. Heart Fail. 13: 1161-1171.
43. Badamchian, M. et al 2003. Thymosinbeta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. Int. Immunopharmacol. 3: 1225-1233.
44. Cavasin, M.A. 2006. Therapeutic potential of thymosin-beta4 and its derivative N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in cardiac healing after infarction. Am. J. Cardiovasc. Drugs 6: 305-311.
45. Girardi, M. et al 2003. Anti-inflammatory effects in the skin of thymosin-beta4 splice-variants. Immunology 109: 1-7.
46. Sosne, G. et al 2002. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp. Eye Res. 74: 293-299.
47. Sosne, G. et al 2005. Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury. Invest. Ophthalmol. Vis. Sci. 46: 2388-2395.
48. Gutierrez, S.H., M.R. Kuri & E.R. del Castillo 2008. Cardiac role of the transcription factor NF-kappaB. Cardiovasc. Hematol. Disord. Drug Targets 8: 153-160.
49. Gordon, J.W., J.A. Shaw & L.A. Kirshenbaum 2011. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ. Res. 108: 1122-1132.
50. Sosne, G. et al 2007. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp. Eye Res. 84: 663-669.
51. Qiu, P. et al 2011. Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. Faseb J. 25: 1815-1826.
52. Creemers, E.E. & Y.M. Pinto 2011. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc. Res. 89: 265-272.
53. Krenning, G., E.M. Zeisberg & R. Kalluri 2010. The origin of fibroblasts and mechanism of cardiac fibrosis. J. Cell. Physiol. 225: 631-637.
54. Espira, L. & M.P. Czubryt 2009. Emerging concepts in cardiac matrix biology. Can. J. Physiol. Pharmacol. 87: 996-1008.
55. Yang, F. et al 2004. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 43: 229-236.
56. Cavasin, M.A. et al 2007. Decreased endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 50: 130-136.
57. Tsutsui, H., S. Kinugawa & S. Matsushima 2011. Oxidative stress and heart failure. Am J. Physiol. Heart Circ. Physiol. 301: H2181-H2190.
58. Afanas'ev, I. 2011. ROS and RNS signaling in heart disorders: could antioxidant treatment be successful Oxid. Med. Cell. Longev. 2011: 293769.
59. Giordano, F.J. 2005. Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 115: 500-508.
60. Ide, T. et al 1999. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 85: 357-363.
61. Murphy, M.P. 2009. How mitochondria produce reactive oxygen species. Biochem. J. 417: 1-13.
62. Ho, J.H. et al 2008. Thymosin beta-4 upregulates anti-oxidative enzymes and protects human cornea epithelial cells against oxidative damage. Br. J. Ophthalmol. 92: 992-997.
63. Kumar, S. & S. Gupta 2011. Thymosin beta 4 prevents oxidative stress by targeting antioxidant and anti-apoptotic genes in cardiac fibroblasts. PLoS One 6: e26912.
64. Weiss, J.N. et al 2003. Role of the mitochondrial permeability transition in myocardial disease. Circ. Res. 93: 292-301.
65. Dai, D.F. et al 2012. Mitochondrial proteome remodelling in pressure overload-induced heart failure: the role of mitochondrial oxidative stress. Cardiovasc. Res. 93: 79-88.
66. Huff, T. et al 2004. Nuclear localisation of the G-actin sequestering peptide thymosin beta4. J. Cell Sci. 117: 5333-5341.
67. Hori, M. & K. Nishida 2009. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc. Res. 81: 457-464.